nach oben

Medical Oncology

Erschienen in:

01.06.2012 | Original Paper

Prognostic value of oncoprotein expressions in thyroid papillary carcinoma

verfasst von: A. Z. Balta, A. I. Filiz, Y. Kurt, I. Sucullu, E. Yucel, M. L. Akin

Erschienen in: Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the expressions of oncoproteins and to correlate the results with clinicopathologic parameters in papillary thyroid carcinoma (PTC). Papillary thyroid cancer (PTC) is the most common form and accounts for about 80% of all thyroid cancers. Although PTC generally has a good prognosis, some patients suffer from local recurrence and/or distant metastasis. Oncogenes have reported to be related not only in carcinogenesis but also in tumor prognosis, tumor type, differentiation and site of tumor in epithelial malignant tumors such as thyroid, breast, ovarian, and stomach cancer. This study was planned retrospectively and was performed in 87 patients (47 PTC, 40 benign lesions). The data of clinicopathologic parameters and tissue samples were collected from the archives. Sections stained with H&E were evaluated for each case and after confirming the diagnosis of PTC, oncoprotein expressions were determined by immunohistochemical analysis. The differences of oncoprotein expressions in PTC compared with control group were statistically significant. Cyclin D1 and p53 expressions were significantly increased in PTC. The expressions of bcl-2 and c-erbB-2 in PTC were found as increased, but the correlation between these proteins and poor prognostic parameters were not significant. We suggest that increased expressions of cyclin D1 and p53 could be used as prognostic factors in patients with PTC.

Melck A, Masoudi H, Griffith OL, Rajput A, Wilkins G, Bugis S, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol. 2007;14:3403–11.PubMedCrossRef

Duntas L, Grab-Duntas BM. Risk and prognostic factors f or differentiated thyroid cancer. Hell J Nucl Med. 2006;9:156–62.PubMed

Cady B, Rossi R. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53.PubMed

Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–95.PubMed

Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1, 779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–8.PubMed

Moore D, Ohene-Finko D, Garcia B, Chakrabarti S. Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression. Histopathology. 1998;32:35–42.PubMedCrossRef

Utrilla JC, Martin-Lacave I, San Martin MV, Fernandez-Santos JM, Galera-Davidson H. Expression of c-erbB-2 oncoprotein in human thyroid tumours. Histopathology. 1999;34:60–5.PubMedCrossRef

Muro-Cacho CA, Holt T, Klotch D, Mora L, Livingston S, Futran N. Cyclin D1 expression as a prognostic parameter in papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg. 1999;120:200–7.PubMedCrossRef

Rojeski MT, Gharib H. Nodular thyroid disease: evaluation and management. N Engl J Med. 1985;313:428–36.PubMedCrossRef

10.

Tantawy A, Youins L, Hamza M. Expression of c-erbB-2 oncoprotein in cancer of the larynx in relation to invasion of the cartilagenous framework and prognosis. Eur Arch Otorhinolaryngol. 1999;256:72–7.PubMedCrossRef

11.

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.PubMedCrossRef

12.

Lazzereschi D, Sambuco L, Carnovale Scalzo C, Ranieri A, Mincione G, Nardi F. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer. 1998;76:806–11.PubMedCrossRef

13.

Zou M, Shi Y, Farid NR, al-Sedairy ST. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocrine. 1998;8:61–4.PubMedCrossRef

14.

Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med. 1987;316:79–84.PubMedCrossRef

15.

Lal G, Clark OH. Thyroid, parathyroid and adrenal. In: Schwartz SI, editor. Principles of surgery. New York: F.C.Brunicardi-Hill Book Comp; 2005. p. 1395–470.

16.

Pilloti S, Collini P, Rike F, Cattoretti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol. 1994;172:337–42.CrossRef

17.

Morita N, Ikeda Y, Takami H. Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg. 2008;32:2617–22.PubMedCrossRef

18.

19.

Horie S, Maeta H, Endo K, Ueta T, Takashima K, Terada T. Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: correlations with clinicopathologic features. Pathol Int. 2001;51:11–5.PubMedCrossRef

20.

Temmim L, Ebraheem AK, Baker H, Sinowatz F. Cyclin D1 protein expression in human thyroid gland and thyroid cancer. Anat Histol Embryol. 2006;35:125–9.PubMedCrossRef

21.

Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA, Khan A. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol. 2000;13:882–7.PubMedCrossRef

22.

Lantsov D, Meirmanov S, Nakashima M, Kondo H, Saenko V, Naruke Y, et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology. 2005;47:248–56.PubMedCrossRef

23.

Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002;87:1814–8.PubMedCrossRef

24.

Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999;26(4 Suppl 12):51–9.PubMed

25.

Carroway KL 3rd, Sweeney C. Localization and modulation of ErbB receptor tyrosine kinases. Curr Opin Cell Biol. 2001;13:1225–30.

26.

Nagy P, Jenei A, Damjanovich S, Jovin TM, Szölosi J. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res. 1999;5:255–71.PubMedCrossRef

27.

Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch. 2003;442:322–8.PubMed

28.

Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997;57:1199–205.PubMed

29.

Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K, et al. Differential expression of the c-erbB-2gene in human small cell and non-small cell lung cancer. Cancer Res. 1989;49:4968–71.PubMed

30.

Yoshida K, Tsuda T, Matsumura T, Tsujino T, Hattori T, Ito H, et al. Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57:285–90.PubMedCrossRef

31.

Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology. 1998;55:475–81.PubMedCrossRef

32.

Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:556–67.PubMed

33.

Freudenberg LS, Sheu S, Görges R, Mann K, Bokler S, Frilling A, et al. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin. 2005;44:179–84.PubMed

34.

Mondi MM, Rich R, Ituarte P, Wong M, Bergman S, Clark OH, et al. HER2 expression in thyroid tumors. Am Surg. 2003;69:1100–3.PubMed

35.

Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c- myc and bcl-2 proto-oncogenes. Nature. 1992;359:554–6.PubMedCrossRef

36.

Mitselou A, Peschos D, Dallas P, Charalabopoulos K, Agnantis NJ, Vougiouklakis T. Immunohistochemical analysis of bcl-2 protein in papillary thyroid carcinomas and papillary microcarcinomas of the thyroid gland. Exp oncol. 2004;26:282–6.PubMed

37.

Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down- regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol. 2005;25:1608–19.PubMedCrossRef

38.

Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S. Expression of bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chir Belg. 2005;105:644–8.PubMed

39.

Mitselou A, Loachim E, Kitsou E, Vougiouklakis Th, Zagorianakou N, Makrydimas G, et al. Immunohistochemical study of apoptosis-related bcl-2 protein and its correlation with proliferation indices (Ki-67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. In vivo. 2003;17:469–77.PubMed

40.

Loachim E, Kitsiou E, Mitselou A, Zagorianakou N, Charalabopoulos K, Salmas M, et al. P21 (waf/cip 1) protein expression in normal, hyperplastic and malignant endometrium. Correlation with hormone receptor status, c-erbB-2 oncoprotein, bcl-2 and other cell cycle related proteins (pb, p53, ki-67, PCNA). Exp Oncol. 2003;25:200–5.

41.

Siironen P, Louhimo J, Nordling S, Ristimaki A, Maenpaa H, Haapiainen R, et al. Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patient. Tumour Biol. 2005;26:57–64.PubMedCrossRef

Titel: Prognostic value of oncoprotein expressions in thyroid papillary carcinoma
verfasst von: A. Z. Balta
A. I. Filiz
Y. Kurt
I. Sucullu
E. Yucel
M. L. Akin
Publikationsdatum: 01.06.2012
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 2/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-011-9969-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Prognostic value of oncoprotein expressions in thyroid papillary carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Nanoparticles targeting HLA-G for gene therapy in cancer

The analysis of CD45 isoforms expression on HBV-specific T cells after liver transplantation

Antitumor activity of total paeony glycoside against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo

O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation

Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence

Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie